Immunogenic cell death (ICD) enhancers—Drugs that enhance the perception of ICD by dendritic cells
Article 2023 en
Authors
PL
Peng Liu
LZ
Liwei Zhao
LZ
Laurence Zitvogel
Abstract
1 min read
The search for immunostimulatory drugs applicable to cancer immunotherapy may profit from target-agnostic methods in which agents are screened for their functional impact on immune cells cultured in vitro without any preconceived idea on their mode of action. We have built a synthetic mini-immune system in which stressed and dying cancer cells (derived from standardized cell lines) are confronted with dendritic cells (DCs, derived from immortalized precursors) and CD8
Jenny Sprooten, Raquel S. Laureano, Isaure Vanmeerbeek, Jannes Govaerts, Stefan Naulaerts, Daniel Borràs, Lisa Kinget, Jitka Fučíková, Radek Špíšek, Lenka Palová Jelínková, Oliver Kepp, Guido Guido Kroemer, Dmitri V. Krysko, An Coosemans, Rianne D.W. Vaes, Dirk De Ruysscher, Steven De Vleeschouwer, Els Wauters, Evelien Smits, Sabine Tejpar, Benoit Beuselinck, Sigrid Hatse, Hans Wildiers, Paul Clement, ,
Noëlia Casares, Marie O. Péquignot, Antoine Tesnière, François Ghiringhelli, S. Roux, Nathalie Chaput, E. Schmitt, Ahmed Hamaï, Sandra Hervás‐Stubbs, Michel Obéid, Frédéric Coutant, Didier Métivier, E Pichard, Pièrre Aucouturier, Gérard Pierron, Carmen Garrido, Laurence Zitvogel, Guido Guido Kroemer
Discussion(0)
No comments yet. Be the first to comment.